By drastically enhancing the effectiveness of CD19 CAR T-cell therapies against lymphoma cells with low or no CD19 antigen expression, Aleta is set to increase B-cell cancer cure rates significantly.

Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...